- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00363298
Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
Double-blind Trial of Acute and Intermediate-term Dextro-amphetamine Versus Caffeine Augmentation in Treatment Resistant Obsessive Compulsive Disorder (OCD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will investigate whether dextro-amphetamine (d-amphetamine) is safe and effective compared to caffeine as an active placebo when used to augment treatment for Obsessive-Compulsive Disorder (OCD), and whether tolerance (loss of therapeutic effect) to the medication will develop over a period of several weeks
D-amphetamine is approved by the U.S. Food and Drug Administration to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Because of the effects that d-amphetamine has on the brain, Dr. Koran believes it may be helpful in treating OCD. A positive finding in this study may stimulate research aimed at improving OCD treatment and understanding of the neurochemistry involved.
This research study will enroll 24 people who are taking medication for their OCD but are not receiving sufficient benefit. The research will be performed only at Stanford University.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- outpatient age 18 through 55 inclusive
- meets DSM-IV criteria for obsessive-compulsive disorder (OCD) with Yale-Brown Obsessive-Compulsive Scale (YBOCS) score greater than or equal to 20
- provides written informed consent
- has taken for at least 12 weeks at least the dose shown of a selective serotonin reuptake inhibitor (SSRI) [citalopram, escitalopram, or fluoxetine 20 mg/d; paroxetine 40 mg/d; sertraline 50 mg/d]; or venlafaxine 225 mg/d; or duloxetine 60 mg/d.
- if taking buspar, gabapentin, an atypical antipsychotic, or a benzodiazepine, dose has been stable for 4 weeks
- has negative urine drug and pregnancy tests
- is practicing reliable birth control method
- has blood pressure readings at screening visit that are less than 140 mm Hg systolic and 90 mm Hg diastolic,
- weight is greater than 100 lbs at screen
Exclusion criteria:
- requires psychotropic medications other than an Serotonin Reuptake Inhibitor (SRI), a benzodiazepine, buspirone, an atypical antipsychotic, and/or gabapentin
- is taking clomipramine
- is taking fluvoxamine
- is taking medication that inhibits hepatic enzyme CYP1A2
- is taking a monoamine oxidase inhibitor
- has co-morbid tics or Tourette's disorder
- has hoarding as the primary or only OCD symptom
- has a history of panic disorder
- has a history of glaucoma
- has a history of seizures
- has a history of schizophrenia or psychotic disorder, or schizotypal personality disorder
- has depression with current suicide risk
- has mental retardation, pervasive developmental disorder, or cognitive disorder
- has a factitious disorder
- has current or past cyclothymic disorder or bipolar disorder
- has a dissociative disorder
- has personality disorder sufficient to interfere with study participation
- has organic mental disorder or dementia
- has current or past substance abuse / dependence (excluding nicotine)
- has current or past anorexia or bulimia
- has serious or unstable medical disorder, including hypertension or cardiac disease
- has history of myocardial infarction or cardiac arrhythmia
- has history of or has current diagnosis of hypertension
- is pregnant or breast-feeding
- is receiving psychotherapy for OCD
- is intending to receive psychotherapy for OCD during the study
- has had a previous trial of d-amphetamine of at least 30 days duration
- is unable to speak, read, or understand English
- is not likely to follow study procedures
- is not suitable for study in the investigator's opinion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: d-amphetamine
dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
|
dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning.
Frequency: once daily.
Duration: 5 weeks.
Other Names:
|
Sham Comparator: Sham comparison
caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
|
caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily.
Duration: 5 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2
Time Frame: At end of week 5, except 1 d-amphetamine subject rated at end of week 2
|
Clinical Global Impressions Scale Improvement Score = 1 (very much improved), or 2 (much improved).
Additional possible scale scores are 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse).
|
At end of week 5, except 1 d-amphetamine subject rated at end of week 2
|
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score
Time Frame: At end of week 5, except 1 d-amphetamine subject rated at end of week 2
|
Yale-Brown Obsessive-Compulsive Scale score by blinded investigator in direct interview.
The scale score is the sum of ten items (5 for obsessions and 5 for compulsions: time occupied, degree of interference with functioning, degree of distress, effort to resist the symptom, success in resisting), each rated from 0 to 4, with higher scores indicating more severe OCD.
Maximum score is 40.
Scores of 14 and below are often described as "subclinical," though patients with these scores may still exhibit troubling symptoms and mild to moderate distress.
A total score of 8 or less is often termed "remission."
A decrease in total score from baseline to endpoint of either 25% or 35% is often used as a "responder" criterion in clinical trials.
|
At end of week 5, except 1 d-amphetamine subject rated at end of week 2
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Personality Disorders
- Anxiety Disorders
- Compulsive Personality Disorder
- Obsessive-Compulsive Disorder
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Caffeine
- Amphetamine
- Dextroamphetamine
Other Study ID Numbers
- 97134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
-
University of South FloridaMassachusetts General HospitalCompletedObsessive-compulsive DisorderUnited States
Clinical Trials on dextro-amphetamine
-
Yale UniversityNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)CompletedHealthy | Nicotine DependenceUnited States
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)CompletedTreatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and PlaceboCocaine-Related DisordersUnited States
-
Reha RheinfeldenTerminated
-
University Hospital, Basel, SwitzerlandCompleted
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR)CompletedPathological GamblingCanada
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH); Brain & Behavior...Completed
-
ShireCompletedAttention Deficit Disorder With HyperactivityUnited States
-
University of Illinois at ChicagoThe University of Texas Health Science Center, HoustonRecruiting
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
ShireCompletedAttention Deficit Disorder With Hyperactivity